Drug Trial Suggests Sunitinib As First-Line Treatment in Metastatic RCC

by: cancercompass

New research suggests sunitinib provides longer survival rates for metastatic renal cell carcinoma (RCC) than interferon alfa.

Phase III trial results for sunitinib's demonstrated superiority over interferon alfa as a first-line treatment were recently published in the Journal of Clinical Oncology.

Researchers randomly assigned either 50 mg of sunitinib orally once daily (4 weeks on, 2 weeks off), or interferon alfa 9 MU subcutaneously thrice weekly to 750 patients with metastatic clear cell RCC.

Reported findings were a greater median overall survival rate in the sunitinib group than the interferon alfa group (26.4 versus 21.8 months, respectively).